Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $27
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Raises Target Price to $28
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Raises Target Price to $28
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
Phathom Pharmaceuticals (PHAT) Gets a Buy From Craig-Hallum
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
Buy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription Growth
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Phathom Pharmaceuticals Analyst Ratings
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
Needham Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
Phathom Pharmaceuticals Analyst Ratings
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
Buy Rating Justified by Phathom Pharmaceuticals' V Oquezna Market Expansion and Positive Prescription Trends